Page last updated: 2024-11-07

sabarubicin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

sabarubicin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID151897
CHEMBL ID1230227
SCHEMBL ID5953752
MeSH IDM0279873

Synonyms (22)

Synonym
sabarubicin
CHEMBL1230227
4'-(o-alpha-l-daunosaminyl)-4-demethoxydoxorubicin
(7s,9s)-7-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7h-tetracene-5,12-dione
211100-13-9
xs499woz93 ,
5,12-naphthacenedione, 7-((4-o-(3-amino-2,3,6-trideoxy-.alpha.-l-lyxo-hexopyranosyl)-2,6-dideoxy-.alpha.-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7s,9s)-
unii-xs499woz93
(7s,9s)-7-{(4-o-(3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)-2,6-dideoxy-alpha-l-lyxo-hexopyranosyl)oxy}-6,9,11-trihydroxy-9-(hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione
sabarubicin [inn]
men 10959
sabarubicin [mart.]
sabarubicin [who-dd]
hexopyranosyl)-2,6-dideoxy-a-l-lyxo-hexopyranosyl)oxy)-6,9,11-trihydroxy-9-(hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione
SCHEMBL5953752
DB12410
(1s,3s)-3,5,12-trihydroxy-3-(hydroxyacetyl)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 4-o-(3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)-2,6-dideoxy-alpha-l-lyxo-hexopyranoside
DTXSID30870233
Q7395917
CS-0007770
HY-13745
5,12-naphthacenedione, 7-[[4-o-(3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)-2,6-dideoxy-alpha-l-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-, (7s,9s)-

Research Excerpts

Overview

Sabarubicin is a third generation anthracycline. It has remarkable antitumor activity in human tumor xenografts.

ExcerptReferenceRelevance
"Sabarubicin (MEN-10755) is a third generation anthracycline, with a remarkable antitumor activity in human tumor xenografts, including doxorubicin-resistant tumors. "( A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer.
Adank, S; Caponigro, F; Capriati, A; Comandini, A; Demol, J; Floquet, A; Sorio, R; Tambaro, R; van Belle, S; Wanders, J; Willemse, P, 2005
)
2.09

Pharmacokinetics

ExcerptReferenceRelevance
" Two pharmacokinetic phase I studies with different dosing schedules were performed in adults with solid refractory malignancies."( Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours.
Aamdal, S; Bortini, S; Bos, AM; Capriati, A; Crea, AE; de Vries, EG; Dombernovsky, P; Hanauske, AR; Roelvink, MW; Schrijvers, D; Uges, DR; Vermorken, JB; Wanders, J, 2001
)
0.31
"Because accurate estimates of pharmacokinetic parameters were achieved, the four-point D-optimal sampling design may be very useful in future studies with MEN-10755."( Development of an optimal sampling strategy for clinical pharmacokinetic studies of the novel anthracycline disaccharide analogue MEN-10755.
Aamdal, S; Boezen, HM; Boom, K; Bos, AM; de Vries, EG; Dombernovsky, P; Uges, DR; Vinks, AA; Wanders, J, 2004
)
0.32
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Dosage Studied

ExcerptRelevanceReference
" Two pharmacokinetic phase I studies with different dosing schedules were performed in adults with solid refractory malignancies."( Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours.
Aamdal, S; Bortini, S; Bos, AM; Capriati, A; Crea, AE; de Vries, EG; Dombernovsky, P; Hanauske, AR; Roelvink, MW; Schrijvers, D; Uges, DR; Vermorken, JB; Wanders, J, 2001
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID459219Binding affinity to d(CGTACG)2 assessed as average residence time2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Interaction between double helix DNA fragments and the new antitumor agent sabarubicin, Men10755.
AID459220Binding affinity to d(CGATCG)2 assessed as average residence time2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Interaction between double helix DNA fragments and the new antitumor agent sabarubicin, Men10755.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (7.41)18.2507
2000's20 (74.07)29.6817
2010's5 (18.52)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.35 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (17.24%)5.53%
Reviews2 (6.90%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (75.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]